On the heels of promis­ing MCL da­ta, Kite hus­tles its 2nd CAR-T to the FDA as the next big race in the field draws to the fin­ish line

Three days af­ter Gilead’s Kite sub­sidiary showed off stel­lar da­ta on their num­ber 2 CAR-T KTE-X19 at ASH, the ex­ec­u­tive team has piv­ot­ed straight to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.